|Doravirine||Non-nucleoside reverse transcriptase inhibitor|
|Lamivudine||Nucleoside reverse transcriptase inhibitor|
|Tenofovir disoproxil||Nucleotide reverse transcriptase inhibitor|
Doravirine/lamivudine/tenofovir disoproxil (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS. It contains doravirine, lamivudine, and tenofovir disoproxil. In the United States, it was approved by the Food and Drug Administration in August 2018 for the treatment of HIV-1 infection.
- "Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co". Adis Insight.
- "FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. August 30, 2018.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|